Cohance Lifesciences said a USFDA inspection of its Jaggaiahpet API manufacturing facility ended with five observations on Form FDA 483. The inspection ran from September 14 to September 19, 2026. The company has started corrective and preventive actions and plans to respond within the prescribed timeline. Investors should track the regulatory follow-up because Jaggaiahpet is an established USFDA-facing API facility.
Cohance Lifesciences Gets 5 USFDA Observations at Jaggaiahpet API Plant
USFDA issued five Form FDA 483 observations after inspecting the Jaggaiahpet facility from September 14-19, 2026.
Cohance Lifesciences has started CAPA and will submit its formal response within the stipulated timeline.
Reader Takeaway: Regulatory remediation is now critical; the facility's established API role keeps the inspection outcome important for investors.
What just happened
Cohance Lifesciences Ltd said the United States Food and Drug Administration completed an inspection of its active pharmaceutical ingredient manufacturing facility at Jaggaiahpet, Andhra Pradesh.
The inspection ran for six days, from September 14 through September 19, and concluded with issuance of Form FDA 483 containing five observations.
A Form 483 records conditions observed by FDA investigators that may require corrective action. It is not by itself a warning letter or import alert.
Why this matters
Jaggaiahpet is one of Cohance Lifesciences' generic API manufacturing facilities and has been inspected by multiple global regulators, including the USFDA.
Any regulatory observation at an export-facing API site matters because customers and regulators closely track manufacturing controls, quality systems and remediation progress.
The filing does not disclose the nature or severity of the five observations. That limits investors' ability to assess the potential operational or commercial impact at this stage.
The backstory
Cohance has faced several USFDA inspections across its manufacturing network in recent months.
Its Pashamylaram facility received five Form 483 observations after an inspection that ended on August 5, 2026. The company said at that time that none of those observations related to data integrity.
Its Shamshabad formulation plant was inspected from August 27 to September 4, 2026 and received four observations. Cohance similarly initiated corrective and preventive actions after that inspection.
Separately, the USFDA issued a warning letter in January 2026 concerning Cohance's Nacharam finished-pharmaceutical manufacturing facility following an August 2025 inspection. That action related to a different site and should not be treated as an outcome of the Jaggaiahpet inspection.
What changes now
Management has initiated corrective and preventive actions, or CAPA, for the Jaggaiahpet observations and intends to submit a formal response within the regulator's required timeline.
The immediate question is whether the USFDA finds the proposed remediation adequate. No warning letter, import alert or other enforcement action relating to this Jaggaiahpet inspection has been disclosed.
Risks to watch
The biggest unknown is the content of the five observations. Without details, investors cannot yet determine whether they relate to routine procedural gaps or more significant manufacturing-control issues.
The frequency of recent USFDA inspections across Cohance's network also makes regulatory execution a key monitorable for shareholders.
What to track next
Investors should watch for any disclosure on the classification or closure of the Jaggaiahpet inspection, the company's CAPA progress and any subsequent communication from the USFDA.
A satisfactory resolution would reduce uncertainty. Any escalation beyond the current Form 483 stage would materially change the regulatory risk assessment.